The @US_FDA has approved a new dosing option for Lilly’s moderate-to-severe atopic dermatitis (#eczema) treatment. Learn more about what this may mean for patients: go.lilly.com/7pxvuy
Eli Lilly and Company
22.4K posts
Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad) e.lilly/guidelines
- That’s a wrap on #ADA2026. It left us with important reminders about why science matters and who it’s for. #WeAreLilly
00:00 - New data: Our oral GLP-1 delivered superior A1C control and weight loss across three clinical trials. Read more: go.lilly.com/dglyiv #ADA2026
- Menopause makes weight loss harder. But post-hoc analyses from two clinical studies of one of our obesity medicines showed what could be possible. Up to 5 in 10 women in one study experienced ≥15% weight loss on the highest dose at 72 weeks. Read more: go.lilly.com/jp5wmu
- Women at every stage of menopause — pre, peri and post — experienced meaningful weight loss in post-hoc analyses of two studies of one of our obesity medicines presented at #ADA2026. Up to 30 pounds lost on the highest dose at 72 weeks. Read more: go.lilly.com/lmdzc7
00:00- Adults with type 2 diabetes on our investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial. Results presented today at #ADA2026 and published simultaneously in @TheLancet. Read more: go.lilly.com/xszmxh
- In addition to weight loss, our investigational triple agonist reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent on the 9 mg dose in the TRIUMPH-1 study. Presented today at #ADA2026. Read more: go.lilly.com/o6k6ge
- It's not just about weight. In TRIUMPH-1, Lilly’s investigational triple agonist reduced knee osteoarthritis pain by an average of 73% at the 12 mg dose and moderate-to-severe obstructive sleep apnea severity by an average of 61% at the 9 mg dose for people living with obesity.
- NEW Phase 3 data today at #ADA2026: Lilly's investigational triple agonist met all primary endpoints in TRIUMPH-1. Patients on the 12 mg dose lost an avg of 70 pounds (28.3%) over 80 weeks. Read more: go.lilly.com/ojwaxj
- We’re focused on advancing science to help people achieve meaningful weight loss — and the additional health benefits that may come with it. On Saturday we’re presenting data from the TRIUMPH-1 study of our investigational triple agonist at #ADA2026. Stay tuned.
00:00 - Treating obesity shouldn't be one-size-fits-all. Rachel Batterham shares why the future of obesity treatment means having medicines that work for people across different stages of their treatment journeys. With #ADA2026 beginning Friday, we're looking forward to sharing new
00:00 - Big news from #ASCO26: data readout from a clinical trial of patients with biomarker-driven early-stage non-small cell #lungcancer. Learn more about these data: go.lilly.com/ekmoh9 #LungCancer #ASCO26
